365 related articles for article (PubMed ID: 22229249)
1. Targeting angiogenesis for treatment of NSCLC brain metastases.
Schettino C; Bareschino MA; Rossi A; Maione P; Sacco PC; Colantuoni G; Rossi E; Gridelli C
Curr Cancer Drug Targets; 2012 Mar; 12(3):289-99. PubMed ID: 22229249
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model.
Masuda C; Sugimoto M; Wakita D; Monnai M; Ishimaru C; Nakamura R; Kinoshita M; Yorozu K; Kurasawa M; Kondoh O; Yamamoto K
Clin Exp Metastasis; 2020 Feb; 37(1):199-207. PubMed ID: 31768815
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab in non-small cell lung cancer.
Di Costanzo F; Mazzoni F; Micol Mela M; Antonuzzo L; Checcacci D; Saggese M; Di Costanzo F
Drugs; 2008; 68(6):737-46. PubMed ID: 18416583
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer.
Rossi A; Maione P; Ferrara ML; Sacco PC; Schettino C; Bareschino MA; Gridelli C
Curr Med Chem; 2009; 16(30):3919-30. PubMed ID: 19747132
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.
Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C
Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044
[TBL] [Abstract][Full Text] [Related]
7. An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases.
Sandler A; Hirsh V; Reck M; von Pawel J; Akerley W; Johnson DH
Lung Cancer; 2012 Oct; 78(1):1-7. PubMed ID: 22877947
[TBL] [Abstract][Full Text] [Related]
8. [Targeted therapies in the treatment of non-small cell lung cancer].
De Grève J; Decoster L; Van Meerbeek J; Vermeij J; Teugels E; Schallier D
Bull Cancer; 2008 Mar; 95(3):358-64. PubMed ID: 18390417
[TBL] [Abstract][Full Text] [Related]
9. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Heist RS; Duda DG; Sahani DV; Ancukiewicz M; Fidias P; Sequist LV; Temel JS; Shaw AT; Pennell NA; Neal JW; Gandhi L; Lynch TJ; Engelman JA; Jain RK
Proc Natl Acad Sci U S A; 2015 Feb; 112(5):1547-52. PubMed ID: 25605928
[TBL] [Abstract][Full Text] [Related]
10. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
11. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
12. Targeting angiogenesis in squamous non-small cell lung cancer.
Piperdi B; Merla A; Perez-Soler R
Drugs; 2014 Mar; 74(4):403-13. PubMed ID: 24578213
[TBL] [Abstract][Full Text] [Related]
13. Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer.
Yano S; Matsumori Y; Ikuta K; Ogino H; Doljinsuren T; Sone S
Int J Clin Oncol; 2006 Apr; 11(2):73-81. PubMed ID: 16622742
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology.
Morgensztern D; Govindan R
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S57-61. PubMed ID: 21885000
[TBL] [Abstract][Full Text] [Related]
15. Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer.
Dowlati A
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S71-5. PubMed ID: 21885002
[TBL] [Abstract][Full Text] [Related]
16. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
Villaruz LC; Socinski MA
Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
[TBL] [Abstract][Full Text] [Related]
17. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
Klamerus JF; Brahmer JR
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
[TBL] [Abstract][Full Text] [Related]
18. [Bevacizumab and non-small cell lung cancer: a new step?].
Pérol M; Arpin D
Rev Mal Respir; 2009 Feb; 26(2):125-38. PubMed ID: 19319108
[TBL] [Abstract][Full Text] [Related]
19. New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer.
Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
Curr Pharm Des; 2015; 21(32):4763-72. PubMed ID: 26219615
[TBL] [Abstract][Full Text] [Related]
20. New antiangiogenetic agents and non-small cell lung cancer.
Gridelli C; Rossi A; Maione P
Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
